The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome
- 31 July 2010
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 9 (9), 609-614
- https://doi.org/10.1016/j.autrev.2010.05.007
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Ectopic Germinal Centers Are Rare in Sjögren’s Syndrome Salivary Glands and Do Not Exclude Autoreactive B CellsPublished by The American Association of Immunologists ,2009
- The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseasesJournal of Autoimmunity, 2008
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)Annals Of The Rheumatic Diseases, 2006
- BAFF‐induced changes in B cell antigen receptor–containing lipid rafts in Sjögren's syndromeArthritis & Rheumatism, 2005
- BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune DiseasesAnnals of the New York Academy of Sciences, 2005
- Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomasRheumatology, 2004
- Sjogren's SyndromeAutoimmunity, 2004
- Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndromeArthritis & Rheumatism, 2002
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994